United States
Search    
Include All CSL Behring Country Sites

Albuminar® 25

Albumin (Human) U.S.P. 25

Albumin (Human) 25% is indicated in the emergency treatment of shock due to burns, trauma, operations, and infections; in the treatment of severe injuries; and in other similar conditions where the restoration of blood volume is urgent.
Albuminar® 25
  • Natural plasma protein product
  • Safe and effective therapy for over 50 years

Broad Therapeutic Applications

  • Plasma expansion and replacement - trauma, burns, and shock
  • Conditions where restoration of blood volume is urgent
  • Hypoproteinemia

Safety at the Source

  • Source plasma screening for human immunodeficiency virus (HIV) 1 and 2 and for other vial indicators, including markers for hepatitis B virus and hepatitis C virus
  • 100% of plasma comes from repeat donors, who are routinely tested at the time of each donation

Effective Viral Inactivation

  • Pasteurization (heat treatment in aqueous solution) at 60°C for 10 hours - a demonstrated viral inactivation method that inactivates lipid-enveloped and certain non-lipid-enveloped viruses
NDC Number
Product Description
0053-7680-32 50 mL
0053-7680-33 100 mL

Important Safety Information

Albuminar® is contraindicated in patients with severe anemia or cardiac failure and in patients with a history of allergic reactions to human albumin.

Albuminar® is derived from human plasma, as with all plasma-derived products, the risk of transmission of infectious agents, including viruses, and theoretically, the Creutzfeldt-Jakob (CJD) disease agent, cannot be completely eliminated. As with any pharmaceutical, the physician should weigh the risks and benefits of administration.

CUSTOMER SUPPORT 1-800-683-1288 or Customer Services

null 31 January 2008